In AD transgenic mouse models (APP/PS1 and 5XFAD), circulating monocytes (CD14+/CD16−) can infiltrate the brain (Table 2), reduce Aβ burden, and improve cognitive performance [208, 212], suggesting a beneficial disease-modifying role for these cells in AD pathology. This evidence concerns the gene APP and Alzheimer disease.